Back to Search
Start Over
Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
- Source :
-
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association [J Stroke Cerebrovasc Dis] 2018 Feb; Vol. 27 (2), pp. 381-390. Date of Electronic Publication: 2017 Oct 27. - Publication Year :
- 2018
-
Abstract
- Background: Intravenous thrombolysis using tissue plasminogen activator (tPA) improves significantly the neurologic function in patients with acute ischemic stroke (AIS). However, it brings financial burden to patients and is associated with symptomatic intracranial hemorrhage (SICH). Whether low-dose tPA can effectively reduce SICH and has the same efficacy as standard-dose tPA is still controversial.<br />Methods: We searched for English clinical trials published before March, 2017on the comparison of the efficacy and safety between low and standard dose of tPA in the treatment of AIS using MEDLINE, Embase, and Cochrane Library. The modified Rankin scale (mRS) score was used as the primary efficacy outcome. The mRS1 corresponded to 0-1, whereas mRS2 corresponded to 0-2. The SICH and mortality were adopted as primary safety outcomes.<br />Results: Twelve high-quality studies were selected, including 7686 patients (low-dose: 2888, standard-dose: 4798). With no statistical heterogeneity, the fixed effects model was adopted in the analysis. Similarly to standard doses, low-dose tPA improved the mRS scores (mRS1: odds ratio [OR] = .92, 95% confidence interval [CI] .84-1.02; P = .12; mRS2: OR = .97, 95% CI .88-1.08; P = .57). Compared with standard-dose tPA, low-dose tPA reduced the incidence of SICH (by National Institute of Neurological Disorders and Stroke [NINDS] definition: OR = .71, 95% CI .57-0.89; P = .003; by Safe Implementation of Thrombolysis in Stroke Monitoring Study [SITS-MOST] definition: OR = .64, 95% CI .42-0.99; P = .04), while both reduced mortality (OR = .87, 95% CI .74-1.02; P = .08).<br />Conclusions: Low-dose tPA is comparable to standard-dose tPA in improving the neurologic function and reducing mortality in AIS patients. Moreover, low-dose tPA can reduce the incidence of SICH compared with standard-dose tPA. Therefore, low-dose tPA is highly recommended in AIS patients.<br /> (Copyright © 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Brain Ischemia diagnosis
Brain Ischemia mortality
Brain Ischemia physiopathology
Chi-Square Distribution
Disability Evaluation
Fibrinolytic Agents adverse effects
Humans
Infusions, Intravenous
Intracranial Hemorrhages chemically induced
Intracranial Hemorrhages prevention & control
Odds Ratio
Recovery of Function
Risk Factors
Stroke diagnosis
Stroke mortality
Stroke physiopathology
Thrombolytic Therapy adverse effects
Thrombolytic Therapy mortality
Time Factors
Tissue Plasminogen Activator adverse effects
Treatment Outcome
Brain Ischemia drug therapy
Fibrinolytic Agents administration & dosage
Stroke drug therapy
Thrombolytic Therapy methods
Tissue Plasminogen Activator administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1532-8511
- Volume :
- 27
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
- Publication Type :
- Academic Journal
- Accession number :
- 29111341
- Full Text :
- https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.014